星空传媒

ESH How to Diagnose and Treat meetings are disease-specific meetings that address up to date diagnostic and clinical management which is greatly facilitated by presentation and discussion of real clinical cases. Intensive interaction between the speakers and participants will be helpful in spreading knowledge. Novel and still evolving insights into the biology and diagnosis of acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease. Recently updates on prognostication and classification of acute leukaemias have been published which will be discussed in various sessions. Chairs: Hervé Dombret, Christoph Röllig, Wendy Stock

The programme of this 鈥淗ow to Diagnose and Treat: Acute Leukaemias鈥� includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell transplantation (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes. Clonal hematopoiesis will be covered in detail. Novel trial designs instrumental for smarter drug development is discussed in a separate session.

This conference is accredited by the European Board for Accreditation in Hematology (EBAH) CME system. Participants will be eligible to claim CME credit points.

The meeting will be of interest to:

鈥� Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)

鈥� Junior scientists and clinicians (MD, PhD)

鈥� PhD candidates and clinical residents still in-training

Learning Objectives:

Knowledge of Classification of ALL and AML

Insight in prognosis of ALL and AML

Application of MRD

Knowledge of established and novel treatment options in ALL and AML

Indications of alloSCT

Management of challenging subgroups of AML and ALL

Controversies on clinical trials and treatment options

Scientific Topics:

鈥�  Dilemmas in acute leukaemias

鈥� Novel treatments

鈥� Diagnosis and treatment of rare diseases and rare subsets

鈥� MRD a proper surrogate endpoint in AML

鈥� Optimizing outcomes in acute leukaemias using supportive strategies

鈥� Immune targeting strategies in ALL

鈥� Real-world AML therapy

鈥� Blina-TKI is enough to cure Ph-positive ALL

鈥� HSC transplantation

鈥� Leukaemia treatment challenges

The programme will include:

- Plenary Sessions

- Interactive Case Presentations

- Roundtables

- Panel Discussions

- Debates

- Poster Walks

- Meet the Expert Sessions

- Voting technology

- Ample time for in-depth discussion

Register

Direct email queries to: [email protected]